Base de dados : MEDLINE
Pesquisa : D02.092.050.500 [Categoria DeCS]
Referências encontradas : 190 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 19 ir para página                         

  1 / 190 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27578074
[Au] Autor:Pereira MP; Ständer S
[Ti] Título:Itch Management: Treatments under Development.
[So] Source:Curr Probl Dermatol;50:71-6, 2016.
[Is] ISSN:1662-2944
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Pruritus is a symptom arising from a plethora of dermatological, neurological, and systemic conditions. The pathophysiological mechanisms involved in the transmission of acute and chronic pruritus are of high complexity and not yet fully understood. Recent research has enhanced the understanding of these mechanisms, enabling the development of novel drugs. Specifically, new therapies for inflammatory dermatoses, uremic pruritus, cholestatic pruritus, cutaneous T-cell lymphoma, and prurigo nodularis are being tested in ongoing randomized clinical trials. Compounds in development include neurokinin 1 receptor antagonists, anti-interleukin-31 receptor A antibodies, nerve growth factor inhibitors, transient receptor potential cation channel V1 antagonists, as well as κ-opioid agonists, ileal bile acid transporter inhibitors, and bile acid sequestrants. Effective treatment options for the various forms of chronic pruritus are still insufficient. Basic research studying additional pathophysiological mechanisms involved in pruritus transmission is urgently needed, as well as clinical trials testing new compounds in patients with chronic pruritus. Moreover, clinical trials including specific patients groups, such as pregnant women or children, are of the utmost importance since only few treatment options are currently approved for these patients. The aim of this chapter is to provide an overview of the drugs under development, highlighting the pathophysiological mechanisms they target.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Antipruriginosos/uso terapêutico
Antagonistas do Receptor de Neuroquinina-1/uso terapêutico
Prurido/tratamento farmacológico
Sequestrantes/uso terapêutico
[Mh] Termos MeSH secundário: Acrilamidas/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Proteínas de Transporte/antagonistas & inibidores
Colestase/complicações
Cloridrato de Colesevelam
Seres Humanos
Linfoma Cutâneo de Células T/complicações
Linfoma Cutâneo de Células T/tratamento farmacológico
Glicoproteínas de Membrana/antagonistas & inibidores
Fator de Crescimento Neural/antagonistas & inibidores
Prurigo/complicações
Prurigo/tratamento farmacológico
Prurido/etiologia
Piridinas/uso terapêutico
Receptores de Interleucina/antagonistas & inibidores
Receptores Opioides kappa/agonistas
Canais de Cátion TRPV/antagonistas & inibidores
Uremia/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acrylamides); 0 (Analgesics, Opioid); 0 (Antibodies, Monoclonal, Humanized); 0 (Antipruritics); 0 (CIM331); 0 (Carrier Proteins); 0 (IL31RA protein, human); 0 (Membrane Glycoproteins); 0 (N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide); 0 (Neurokinin-1 Receptor Antagonists); 0 (Pyridines); 0 (Receptors, Interleukin); 0 (Receptors, Opioid, kappa); 0 (Sequestering Agents); 0 (TRPV Cation Channels); 0 (bile acid binding proteins); 9061-61-4 (Nerve Growth Factor); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1159/000446046


  2 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27539104
[Au] Autor:Blahová T; Peterková L; Lenícek M; Vlachová M; Zemánková K; Adámková V; Vítek L; Kovár J
[Ad] Endereço:Institute for Clinical and Experimental Medicine, Prague, Czech Republic. jan.kovar@ikem.cz.
[Ti] Título:The effect of colesevelam treatment on bile acid and lipid metabolism and glycemic control in healthy men.
[So] Source:Physiol Res;65(6):995-1003, 2016 Dec 13.
[Is] ISSN:1802-9973
[Cp] País de publicação:Czech Republic
[La] Idioma:eng
[Ab] Resumo:The treatment of hypercholesterolemia with bile acid (BA) sequestrants results in upregulation of BA synthesis through the classical pathway initiated by cholesterol 7alpha-hydroxylase (CYP7A1). To characterize the detailed dynamics of serum lipid and BA concentrations and the BA synthesis rate in response to treatment with BA sequestrants and to determine whether the -203A/C promoter polymorphism of the CYP7A1 encoding gene (CYP7A1) affects such a response, this pilot study was carried out in healthy men (8 homozygous for the -203A allele and 8 homozygous for the -203C allele of CYP7A1). The subjects were treated for 28 days with colesevelam and blood was drawn for analysis before and on days 1, 3, 7, 14 and 28 of treatment. The response of lipids, BA, fibroblast growth factor-19 (FGF19) and 7alpha-hydroxy-4-cholesten-3-one (C4) to colesevelam did not differ between carriers of -203A and -203C alleles; their data were then aggregated for further analysis. Colesevelam treatment caused immediate suppression of FGF19 concentration and a fivefold increase in CYP7A1 activity, as assessed from C4 concentration, followed by a 17 % decrease in LDL-cholesterol. Although total plasma BA concentrations were not affected, the ratio of cholic acid/total BA rose from 0.25+/-0.10 to 0.44+/-0.16 during treatment at the expense of decreases in chenodeoxycholic and deoxycholic acid.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Glicemia/metabolismo
Colagogos e Coleréticos/farmacologia
Cloridrato de Colesevelam/farmacologia
Metabolismo dos Lipídeos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Alelos
Colestenonas/sangue
Colesterol 7-alfa-Hidroxilase/genética
Colesterol 7-alfa-Hidroxilase/metabolismo
LDL-Colesterol/sangue
Fatores de Crescimento de Fibroblastos/metabolismo
Genótipo
Voluntários Saudáveis
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Polimorfismo Genético
Hormônios Tireóideos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bile Acids and Salts); 0 (Blood Glucose); 0 (Cholagogues and Choleretics); 0 (Cholestenones); 0 (Cholesterol, LDL); 0 (FGF19 protein, human); 0 (Thyroid Hormones); 3862-25-7 (7 alpha-hydroxy-4-cholesten-3-one); 62031-54-3 (Fibroblast Growth Factors); EC 1.14.14.23 (CYP7A1 protein, human); EC 1.14.14.23 (Cholesterol 7-alpha-Hydroxylase); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170330
[Lr] Data última revisão:
170330
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160820
[St] Status:MEDLINE


  3 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27191492
[Au] Autor:Morgan B
[Ti] Título:Drug development: A healthy pipeline.
[So] Source:Nature;533(7603):S116-7, 2016 05 19.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome do Intestino Irritável/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Benzimidazóis/uso terapêutico
Benzofuranos/uso terapêutico
Ácidos e Sais Biliares/metabolismo
Carbolinas/efeitos adversos
Cloridrato de Colesevelam/uso terapêutico
Colestipol/uso terapêutico
Modelos Animais de Doenças
Sistema Nervoso Entérico/fisiopatologia
Feminino
Seres Humanos
Imidazóis/uso terapêutico
Indóis/efeitos adversos
Síndrome do Intestino Irritável/complicações
Síndrome do Intestino Irritável/fisiopatologia
Loperamida/uso terapêutico
Lubiprostona/uso terapêutico
Masculino
Camundongos
Peptídeos Natriuréticos/uso terapêutico
Peptídeos/uso terapêutico
Fenilalanina/análogos & derivados
Fenilalanina/uso terapêutico
Receptores 5-HT3 de Serotonina/metabolismo
Receptores 5-HT4 de Serotonina/metabolismo
Rifamicinas/uso terapêutico
Serotonina/metabolismo
Antagonistas da Serotonina/uso terapêutico
Agonistas de Receptores de Serotonina/uso terapêutico
Dor Visceral/complicações
Dor Visceral/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzimidazoles); 0 (Benzofurans); 0 (Bile Acids and Salts); 0 (Carbolines); 0 (Imidazoles); 0 (Indoles); 0 (Natriuretic Peptides); 0 (Peptides); 0 (Receptors, Serotonin, 5-HT3); 0 (Rifamycins); 0 (Serotonin Antagonists); 0 (Serotonin Receptor Agonists); 0A09IUW5TP (prucalopride); 13Z9HTH115 (alosetron); 158165-40-3 (Receptors, Serotonin, 5-HT4); 333DO1RDJY (Serotonin); 458VC51857 (tegaserod); 45TPJ4MBQ1 (eluxadoline); 47E5O17Y3R (Phenylalanine); 6X9OC3H4II (Loperamide); 7662KG2R6K (Lubiprostone); 7IK8Z952OK (plecanatide); 7ZRO0SC54Y (ramosetron); K50N755924 (Colestipol); L36O5T016N (rifaximin); N0TXR0XR5X (linaclotide); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE
[do] DOI:10.1038/533S116a


  4 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27079339
[Au] Autor:Sterrett JJ; Bragg S; Weart CW
[Ad] Endereço:South Carolina College of Pharmacy, Charleston, South Carolina. Electronic address: sterrejj@musc.edu.
[Ti] Título:Type 2 Diabetes Medication Review.
[So] Source:Am J Med Sci;351(4):342-55, 2016 Apr.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with type 2 diabetes and their healthcare providers have a variety of medication options available for treating elevated blood glucose values. These medication choices have expanded drastically over the last 10 years with a large number of glucose lowering medications gaining FDA approval. METHODS: Here, we have included an extensive search of the type 2 diabetes literature focusing on articles which impact patient-oriented evidence that maters (POEMs). RESULTS: Choosing the best agent(s) can be challenging and requires weighing the risks and benefits of each particular medication. Tailoring medications to individual patients should be prioritized based on trials with cardiovascular outcome data, potential hemoglobin A1c reduction/goal, serious medication precautions and side-effects, co-morbid medical conditions, and cost. CONCLUSIONS: This paper will provide the reader with an overview of the pros and cons for each antiglycemic medication class and specific drugs where appropriate. Data relevant to most patient centered encounters will be provided, including safety, tolerability, efficacy, cost, and simplicity of use.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Revisão de Uso de Medicamentos/métodos
Hipoglicemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Anticolesterolemiantes/efeitos adversos
Anticolesterolemiantes/uso terapêutico
Cloridrato de Colesevelam/efeitos adversos
Cloridrato de Colesevelam/uso terapêutico
Diabetes Mellitus Tipo 2/diagnóstico
Diabetes Mellitus Tipo 2/epidemiologia
Revisão de Uso de Medicamentos/normas
Seres Humanos
Hipoglicemiantes/efeitos adversos
Insulina/efeitos adversos
Insulina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Hypoglycemic Agents); 0 (Insulin); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160415
[Lr] Data última revisão:
160415
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160416
[St] Status:MEDLINE


  5 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26913381
[Au] Autor:Mottacki N; Simrén M; Bajor A
[Ad] Endereço:Department of Internal Medicine & Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
[Ti] Título:Review article: bile acid diarrhoea - pathogenesis, diagnosis and management.
[So] Source:Aliment Pharmacol Ther;43(8):884-898, 2016 Apr.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bile acid diarrhoea results from imbalances in the homoeostasis of bile acids in the enterohepatic circulation. It can be a consequence of ileal disease/dysfunction, associated with other GI pathology or can be idiopathic. AIMS: To summarise the different types of bile acid diarrhoea and discuss the currently available diagnostic methods and treatments. RESULTS: Bile acid diarrhoea is found in up to 40% of patients diagnosed as having functional diarrhoea/IBS-D, and in up to 80% of patients who have undergone ileal resection. It is likely under-diagnosed and under-treated. In idiopathic disease, errors in regulation feedback of fibroblast growth factor 19 contribute to the development of the condition. Clinical therapeutic trials for bile acid diarrhoea have been used to diagnose it, but the SeHCAT test is the primary current method. It is sensitive, specific and widely available, though not in the USA. Other diagnostic methods (such as serum measurement of the bile acid intermediate 7α-hydroxy-4-cholesten-3-one, or C4) have less widespread availability and documentation, and some (such as faecal measurement of bile acids) are significantly more complex and costly. First-line treatment of bile acid diarrhoea is with the bile acid sequestrant cholestyramine, which can be difficult to administer and dose due to gastrointestinal side effects. These side effects are less prominent in newer agents such as colesevelam, which may provide higher efficacy, tolerability and compliance. CONCLUSION: Bile acid diarrhoea is common, and likely under-diagnosed. Bile acid diarrhoea should be considered relatively early in the differential diagnosis of chronic diarrhoea.
[Mh] Termos MeSH primário: Ácidos e Sais Biliares/metabolismo
Diarreia/etiologia
Circulação Êntero-Hepática
[Mh] Termos MeSH secundário: Resina de Colestiramina/uso terapêutico
Cloridrato de Colesevelam/uso terapêutico
Diagnóstico Diferencial
Diarreia/diagnóstico
Fezes
Fatores de Crescimento de Fibroblastos/metabolismo
Seres Humanos
Intestinos/metabolismo
Ácido Taurocólico/análogos & derivados
Ácido Taurocólico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bile Acids and Salts); 0 (FGF19 protein, human); 11041-12-6 (Cholestyramine Resin); 5E090O0G3Z (Taurocholic Acid); 62031-54-3 (Fibroblast Growth Factors); 75018-70-1 (23-seleno-25-homotaurocholic acid); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160226
[St] Status:MEDLINE
[do] DOI:10.1111/apt.13570


  6 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26888164
[Au] Autor:Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
[Ad] Endereço:Center for Diabetes Research, Gentofte Hospital, University Copenhagen, Hellerup, Denmark.
[Ti] Título:Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
[So] Source:Diabetes Obes Metab;18(6):571-80, 2016 Jun.
[Is] ISSN:1463-1326
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: To evaluate the effects of the primary human bile acid, chenodeoxycholic acid (CDCA), and the bile acid sequestrant (BAS) colesevelam, instilled into the stomach, on plasma levels of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, glucose, insulin, C-peptide, glucagon, cholecystokinin and gastrin, as well as on gastric emptying, gallbladder volume, appetite and food intake. METHODS: On four separate days, nine patients with type 2 diabetes, and 10 matched healthy control subjects received bolus instillations of (i) CDCA, (ii) colesevelam, (iii) CDCA + colesevelam or (iv) placebo. At baseline and for 180 min after instillation, blood was sampled. RESULTS: In both the type 2 diabetes group and the healthy control group, CDCA elicited an increase in GLP-1 levels compared with colesevelam, CDCA + colesevelam and placebo, respectively (p < 0.05). The interventions did not affect plasma glucose, insulin or C-peptide concentrations in any of the groups. CDCA elicited a small increase in plasma insulin : glucose ratio compared with colesevelam, CDCA + colesevelam and placebo in both groups. Compared with colesevelam, CDCA + colesevelam and placebo, respectively, CDCA increased glucagon and delayed gastric emptying in both groups. CONCLUSIONS: CDCA increased GLP-1 and glucagon secretion, and delayed gastric emptying. We speculate that bile acid-induced activation of TGR5 on L cells increases GLP-1 secretion, which, in turn, may result in amplification of glucose-stimulated insulin secretion. Furthermore our data suggest that colesevelam does not have an acute effect on GLP-1 secretion in humans.
[Mh] Termos MeSH primário: Ácido Quenodesoxicólico/farmacologia
Cloridrato de Colesevelam/farmacologia
Diabetes Mellitus Tipo 2/metabolismo
Peptídeo 1 Semelhante ao Glucagon/secreção
[Mh] Termos MeSH secundário: Idoso
Ácidos e Sais Biliares/antagonistas & inibidores
Ácidos e Sais Biliares/metabolismo
Glicemia/efeitos dos fármacos
Glicemia/metabolismo
Peptídeo C/sangue
Diabetes Mellitus Tipo 2/sangue
Método Duplo-Cego
Feminino
Esvaziamento Gástrico/efeitos dos fármacos
Peptídeo 1 Semelhante ao Glucagon/sangue
Seres Humanos
Incretinas/sangue
Insulina/sangue
Insulina/secreção
Masculino
Meia-Idade
Placebos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Bile Acids and Salts); 0 (Blood Glucose); 0 (C-Peptide); 0 (Incretins); 0 (Insulin); 0 (Placebos); 0GEI24LG0J (Chenodeoxycholic Acid); 89750-14-1 (Glucagon-Like Peptide 1); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160219
[St] Status:MEDLINE
[do] DOI:10.1111/dom.12648


  7 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26881721
[Au] Autor:Katare PB; Banerjee SK
[Ti] Título:Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
[So] Source:Curr Top Med Chem;16(19):2189-200, 2016.
[Is] ISSN:1873-4294
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cardiometabolic disorder (CMD) is a cluster of diseases, including cardiovascular diseases (CVDs), metabolic syndrome (MS) and diabetes mellitus (DM). Cardiometabolic disorders (CMDs) remain the principal cause of death in both developed and developing countries, accounting for nearly 32% of all deaths worldwide per year. In addition, dyslipidemia, angina, arrhythmia, cardiac failure, myocardial infarction (MI), and diabetes mellitus represent the leading killer with an estimated 19 million people died from CMDs in 2012. By 2030 more than 23 million people will die annually from CVDs. Existing drugs are not efficient enough to reduce the disease burden as well as mortality. Therefore, there is an urgent demand for new drugs in this area to reduce the mortality and control the associated disability. Nonetheless, new drug discovery (NDD) in CMDs has become more challenging for last couple of decades due to increased expenses and decreased success rate. In such a scenario, drug repositioning in the CMDs appears promising for introducing existing drugs for new therapeutic indication. Repositioning is quite an old strategy dating back to 1960s and mainly followed by serendipitous observations during clinical use of drugs. A major advantage of repositioning is that the safety profile of the drug is well established thus reducing the chances of failure due to adverse toxic effects. In addition, repositioning requires less time and investment than NDD. Considering these facts, pharmaceutical companies are now becoming increasingly interested in drug repositioning. In this follow-up, we have talked about the concept of repositioning with important examples of repositioned drugs in cardiometabolic disorder.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/tratamento farmacológico
Avaliação Pré-Clínica de Medicamentos/métodos
Reposicionamento de Medicamentos/métodos
Síndrome Metabólica/tratamento farmacológico
[Mh] Termos MeSH secundário: Alopurinol/farmacologia
Aspirina/farmacologia
Bromocriptina/farmacologia
Clonidina/farmacologia
Cloridrato de Colesevelam/farmacologia
Diabetes Mellitus/tratamento farmacológico
Descoberta de Drogas
Seres Humanos
Piperazinas/farmacologia
Tadalafila/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Piperazines); 3A64E3G5ZO (Bromocriptine); 63CZ7GJN5I (Allopurinol); 742SXX0ICT (Tadalafil); 90X28IKH43 (vanoxerine); MN3L5RMN02 (Clonidine); P4SG24WI5Q (Colesevelam Hydrochloride); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160217
[St] Status:MEDLINE


  8 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26584788
[Au] Autor:Sandhu S; Moosavi M; Golmohammadi K; Francis GA
[Ad] Endereço:Division of Endocrinology and Metabolism, Healthy Heart Program Prevention Clinic and Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada.
[Ti] Título:Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes.
[So] Source:Can J Diabetes;40(2):112-4, 2016 Apr.
[Is] ISSN:2352-3840
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Cloridrato de Colesevelam/uso terapêutico
Diabetes Mellitus Tipo 2/tratamento farmacológico
Dislipidemias/prevenção & controle
Hiperglicemia/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticholesteremic Agents); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151121
[St] Status:MEDLINE


  9 / 190 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26134028
[Au] Autor:Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
[Ad] Endereço:1] European Genomic Institute for Diabetes (EGID), FR 3508, Lille F-59000, France [2] Université de Lille, Lille F-59000, France [3] INSERM UMR 1011, Lille F-59000, France [4] Institut Pasteur de Lille, Lille F-59000, France.
[Ti] Título:Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
[So] Source:Nat Commun;6:7629, 2015 Jul 02.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bile acids are signalling molecules, which activate the transmembrane receptor TGR5 and the nuclear receptor FXR. BA sequestrants (BAS) complex bile acids in the intestinal lumen and decrease intestinal FXR activity. The BAS-BA complex also induces glucagon-like peptide-1 (GLP-1) production by L cells which potentiates ß-cell glucose-induced insulin secretion. Whether FXR is expressed in L cells and controls GLP-1 production is unknown. Here, we show that FXR activation in L cells decreases proglucagon expression by interfering with the glucose-responsive factor Carbohydrate-Responsive Element Binding Protein (ChREBP) and GLP-1 secretion by inhibiting glycolysis. In vivo, FXR deficiency increases GLP-1 gene expression and secretion in response to glucose hence improving glucose metabolism. Moreover, treatment of ob/ob mice with the BAS colesevelam increases intestinal proglucagon gene expression and improves glycaemia in a FXR-dependent manner. These findings identify the FXR/GLP-1 pathway as a new mechanism of BA control of glucose metabolism and a pharmacological target for type 2 diabetes.
[Mh] Termos MeSH primário: Células Enteroendócrinas/metabolismo
Peptídeo 1 Semelhante ao Glucagon/genética
Intestinos/metabolismo
RNA Mensageiro/metabolismo
Receptores Citoplasmáticos e Nucleares/genética
[Mh] Termos MeSH secundário: Animais
Anticolesterolemiantes/farmacologia
Fatores de Transcrição de Zíper de Leucina e Hélice-Alça-Hélix Básicos/metabolismo
Ácidos e Sais Biliares/metabolismo
Glicemia/metabolismo
Cloridrato de Colesevelam/farmacologia
Colo/citologia
Colo/metabolismo
Dieta Hiperlipídica
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Glicólise
Seres Humanos
Íleo/citologia
Íleo/metabolismo
Insulina/secreção
Células Secretoras de Insulina/secreção
Intestinos/citologia
Jejuno/citologia
Jejuno/metabolismo
Camundongos
Camundongos Knockout
Camundongos Obesos
Proteínas Nucleares/metabolismo
Obesidade/genética
Obesidade/metabolismo
Proglucagon/efeitos dos fármacos
Proglucagon/genética
Proglucagon/metabolismo
Receptores Acoplados a Proteínas-G/genética
Sequestrantes/farmacologia
Transdução de Sinais
Fatores de Transcrição/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors); 0 (Bile Acids and Salts); 0 (Blood Glucose); 0 (Gpbar1 protein, mouse); 0 (Insulin); 0 (MLXIPL protein, human); 0 (Mlxipl protein, mouse); 0 (Nuclear Proteins); 0 (RNA, Messenger); 0 (Receptors, Cytoplasmic and Nuclear); 0 (Receptors, G-Protein-Coupled); 0 (Sequestering Agents); 0 (Transcription Factors); 0 (farnesoid X-activated receptor); 55963-74-1 (Proglucagon); 89750-14-1 (Glucagon-Like Peptide 1); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150703
[St] Status:MEDLINE
[do] DOI:10.1038/ncomms8629


  10 / 190 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26043746
[Au] Autor:Ross S; D'Mello M; Anand SS; Eikelboom J; Stewart AF; Samani NJ; Roberts R; Paré G; CARDIoGRAMplusC4D Consortium
[Ad] Endereço:From the Population Health Research Institute, Hamilton Health Sciences (S.R., M.D'M., S.S.A., J.E., G.P.), Department of Clinical Epidemiology & Biostatistics, Population Genomics Program (S.R., M.D'M., S.S.A., G.P.), Population Genomics Program, Chanchlani Research Centre (S.R., M.D'M., S.S.A.
[Ti] Título:Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis.
[So] Source:Circ Cardiovasc Genet;8(4):618-27, 2015 Aug.
[Is] ISSN:1942-3268
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Statins lower low-density lipoprotein cholesterol (LDL-C) and risk of coronary artery disease (CAD), but they may be ineffective or not tolerated. Bile acid sequestrants (BAS) reduce LDL-C, yet their clinical efficacy on CAD remains controversial. METHODS AND RESULTS: We conducted a systematic review and meta-analysis of randomized controlled trials to assess the effect of cholestyramine and colesevelam. We then used Mendelian randomization to estimate the effect of BAS on reducing the risk of CAD. First, we quantified the effect of rs4299376 (ABCG5/ABCG8), which affects the intestinal cholesterol absorption pathway targeted by BAS and then we used these estimates to predict the effect of BAS on CAD. Nineteen randomized controlled trials with a total of 7021 study participants were included. Cholestyramine 24 g/d was associated with a reduction in LDL-C of 23.5 mg/dL (95% confidence interval [CI] -26.8,-20.2; N=3806) and a trend toward reduced risk of CAD (odds ratio 0.81, 95% CI 0.70-1.02; P=0.07; N=3806), whereas colesevelam 3.75 g/d was associated with a reduction in LDL-C of 22.7 mg/dL (95% CI -28.3, -17.2; N=759). Based on the findings that rs4299376 was associated with a 2.75 mg/dL decrease in LDL-C and a 5% decrease in risk of CAD outcomes, we estimated that cholestyramine was associated with an odds ratio for CAD of 0.63 (95% CI 0.52-0.77; P=6.3×10(-6)) and colesevelam with an odds ratio of 0.64 (95% CI 0.52-0.79, P=4.3×10(-5)), which were not statistically different from BAS clinical trials (P>0.05). CONCLUSIONS: The cholesterol lowering effect of BAS may translate into a clinically relevant reduction in CAD.
[Mh] Termos MeSH primário: Anticolesterolemiantes/uso terapêutico
Ácidos e Sais Biliares/metabolismo
Resina de Colestiramina/uso terapêutico
Cloridrato de Colesevelam/uso terapêutico
Doença da Artéria Coronariana/tratamento farmacológico
[Mh] Termos MeSH secundário: Membro 5 da Subfamília G de Transportadores de Cassetes de Ligação de ATP
Membro 8 da Subfamília G de Transportadores de Cassetes de Ligação de ATP
Transportadores de Cassetes de Ligação de ATP/genética
Transportadores de Cassetes de Ligação de ATP/metabolismo
Anticolesterolemiantes/metabolismo
LDL-Colesterol/antagonistas & inibidores
LDL-Colesterol/metabolismo
Resina de Colestiramina/metabolismo
Cloridrato de Colesevelam/metabolismo
Doença da Artéria Coronariana/genética
Doença da Artéria Coronariana/metabolismo
Seres Humanos
Lipoproteínas/genética
Lipoproteínas/metabolismo
Análise da Randomização Mendeliana/métodos
Polimorfismo de Nucleotídeo Único
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (ABCG5 protein, human); 0 (ABCG8 protein, human); 0 (ATP Binding Cassette Transporter, Sub-Family G, Member 5); 0 (ATP Binding Cassette Transporter, Sub-Family G, Member 8); 0 (Anticholesteremic Agents); 0 (Bile Acids and Salts); 0 (Cholesterol, LDL); 0 (Lipoproteins); 11041-12-6 (Cholestyramine Resin); P4SG24WI5Q (Colesevelam Hydrochloride)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150606
[St] Status:MEDLINE
[do] DOI:10.1161/CIRCGENETICS.114.000952



página 1 de 19 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde